Ausgabe 2/2013
Inhalt (30 Artikel)
Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies
Amnon C. Sintov, Liron Berkovich, Shimon Ben-Shabat
Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin
Laurent Schwartz, Adeline Guais, Maurice Israël, Bernard Junod, Jean-Marc Steyaert, Elisabetta Crespi, Gianfranco Baronzio, Mohammad Abolhassani
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258
Stefan Vallo, Jens Mani, Matthias Stastny, Jasmina Makarević, Eva Juengel, Igor Tsaur, Georg Bartsch, Axel Haferkamp, Roman A. Blaheta
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
Céline Clémenson, Erwan Jouannot, Ana Merino-Trigo, Chantal Rubin-Carrez, Eric Deutsch
Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer
Etchison Ryan, A. Jacobson Blake, A. Benoit, M. Ferguson David, A. Kratzke Robert
Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line
Roudy Chiminch Ekyalongo, Toru Mukohara, Yu Kataoka, Yohei Funakoshi, Hideo Tomioka, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor
Anne-Sophie Belzacq-Casagrande, Florence Bachelot, Catherine De Oliveira, Séverine Coutadeur, Florence Maurier-Mahé, Emeline Throo, Cédric Chauvignac, Laure Pognante, Angélique Petibon, Thierry Taverne, Eric Beausoleil, Bertrand Leblond, Matthew P. Pando, Laurent Désiré
Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues
Jintapat Nateewattana, Rungnapha Saeeng, Sakkasem Kasemsook, Kanoknetr Suksen, Suman Dutta, Surawat Jariyawat, Arthit Chairoungdua, Apichart Suksamrarn, Pawinee Piyachaturawat
Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation
Elad Milrot, Anna Jackman, Eliezer Flescher, Pinhas Gonen, Itzhak Kelson, Yona Keisari, Levana Sherman
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer
Nilofer Azad, Arvind Dasari, John Arcaroli, Gretchen E. Taylor, Daniel A. Laheru, Michael A. Carducci, Martine McManus, Kevin Quackenbush, John J. Wright, Manuel Hidalgo, Luis A. Diaz Jr., Ross C. Donehower, Ming Zhao, Michelle A. Rudek, Wells A. Messersmith
A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies
John F. Gerecitano, Joe J. Stephenson, Nancy L. Lewis, Anna Osmukhina, Jianguo Li, Kaida Wu, Zhiping You, Dennis Huszar, Jeffrey M. Skolnik, Gary K. Schwartz
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET
Jeffrey R. Infante, Terence Rugg, Michael Gordon, Isabelle Rooney, Lee Rosen, Karin Zeh, Raymond Liu, Howard A. Burris, Ramesh K. Ramanathan
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
Gary K. Schwartz, Richard D. Carvajal, Rachel Midgley, Scott J. Rodig, Paul K. Stockman, Ozlem Ataman, David Wilson, Shampa Das, Geoffrey I. Shapiro
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole
L. A. Devriese, M. Mergui-Roelvink, J. Wanders, A. Jenner, G. Edwards, L. Reyderman, W. Copalu, F. Peng, S. Marchetti, J. H. Beijnen, J. H. M. Schellens
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer
C. Gómez-Martín, R. Salazar, C. Montagut, M. Gil-Martín, J. A. Núñez, M. Puig, X. Lin, R. Khosravan, J. M. Tursi, M. J. Lechuga, J. Bellmunt
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
John Marshall, Jimmy Hwang, Ferry A. L. M. Eskens, Herman Burger, Shakun Malik, Martina Uttenreuther-Fischer, Peter Stopfer, Mahmoud Ould-Kaci, Roger B. Cohen, Nancy L Lewis
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
Michael S. Gordon, David S. Mendelson, Mitchell Gross, Martina Uttenreuther-Fischer, Mahmoud Ould-Kaci, Yihua Zhao, Peter Stopfer, David B. Agus
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Tanguy Seiwert, John Sarantopoulos, Howard Kallender, Stewart McCallum, Harold N. Keer, George Blumenschein Jr.
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
Patrick A. Ott, Richard D. Carvajal, Neeta Pandit-Taskar, Achim A. Jungbluth, Eric W. Hoffman, Bor-Wen Wu, John S. Bomalaski, Ralph Venhaus, Linda Pan, Lloyd J. Old, Anna C. Pavlick, Jedd D. Wolchok
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer
Bryan J. Schneider, Julia Shin-Jung Lee, James A. Hayman, Andrew C. Chang, Mark B. Orringer, Allan Pickens, Charlie C. Pan, Sofia D. Merajver, Susan G. Urba
Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma
Yumiko Aoyama, Atsunori Kaibara, Akitsugu Takada, Tetsuya Nishimura, Masataka Katashima, Taiji Sawamoto
The inhibitor of Ca2+-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB
Christian Freise, Martin Ruehl, Daniel Seehofer, Joachim Hoyer, Rajan Somasundaram
The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells
Maria Grazia di Iasio, Giorgio Zauli
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines
David Davidson, Yunzhe Wang, Raquel Aloyz, Lawrence Panasci
Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma
Hee Kyung Ahn, Seok Jin Kim, Deok Won Hwang, Young Hyeh Ko, Tiffany Tang, Soon Thye Lim, Won Seog Kim
Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin
Tetsuya Tanimoto, Masaharu Tsubokura, Jinichi Mori, Monika Pietrek, Shunsuke Ono, Masahiro Kami
Clinical trial design in biosimilar drug development
G. Dranitsaris, K. Dorward, E. Hatzimichael, E. Amir
Erratum to: Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis
Gopalakrishnan Ramakrishnan, Sundaram Jagan, Sattu Kamaraj, Pandi Anandakumar, Thiruvengadam Devaki
Erratum to: Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies
Liron Berkovich, Amnon C. Sintov, Shimon Ben-Shabat